Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
Healthcare
$16.54 -1.28%
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
52W Low $16.50High $37.50
Volume 0.01M
Average 0.04M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$22.59M
FY 2025 · Annual
Investing Cash Flow
-$5.24M
FY 2025 · Annual
Financing Cash Flow
$45.34M
FY 2025 · Annual
+630.1% YoYCash Flow Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (2.46M) | (7.38M) | (7.96M) | (43.32M) |
| Depreciation & Amortization | 0 | 0 | 0 | 2.36M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 110.15K | 1.73M | 1.8M | 0 |
| Change in Working Capital | 640.86K | 2.05M | 34.63K | (6.07M) |
| Accounts Receivables | 0 | 0 | (45.79K) | (8.81M) |
| Inventory | 0 | 0 | 0 | 1.78M |
| Accounts Payables | 413.6K | 1.63M | 1.18M | 1.36M |
| Other Working Capital | 227.26K | 424.07K | (1.1M) | (395K) |
| Other Non-Cash Items | 140.43K | 2.62M | 328.93K | 24.44M |
| Operating Cash Flow | (1.57M) | (981.03K) | (5.79M) | (22.59M) |
| Capital Expenditures | 0 | 0 | 0 | (99K) |
| Acquisitions (Net) | 0 | 0 | 0 | (5.14M) |
| Purchases of Investments | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (5.24M) |
| Debt Repayment | 400K | 766.94K | 321.43K | 17.75M |
| Common Stock Issued | 0 | 255.41K | 6.05M | 27.59M |
| Common Stock Repurchased | 0 | 0 | (166.51K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.22M | 0 | 0 | 0 |
| Financing Cash Flow | 1.62M | 1.02M | 6.21M | 45.34M |
| Effect of Forex Changes | 0 | 0 | 0 | (443) |
| Net Change in Cash | 55.07K | 41.32K | 417.05K | 17.51M |
| Free Cash Flow | (1.57M) | (981.03K) | (5.79M) | (22.69M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$43.3M
+ D&A$2.4M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$6.1M
+ Other Non-Cash$24.4M
= Operating Cash Flow-$22.6M
- Capex-$99.0K
= Free Cash Flow-$22.7M
Analysis
FY2025 free cash flow is -$22.7M. FCF conversion is 52.4% of net income. Operating cash flow was -$22.6M, with capex of -$99.0K. The largest bridge item is Other Non-Cash at $24.4M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | May 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 26, 2026 | |
| 144 | Notice of proposed sale of securities | May 22, 2026 | |
| 8-K | Current report | May 21, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 18, 2026 |
Does PTHS generate free cash flow?
Pelthos Therapeutics Inc. (PTHS) generated -$22.69M of free cash flow in fiscal 2025.
How much operating cash flow does PTHS produce?
Operating cash flow was -$22.59M, before capital expenditures of $99,000.00.
Continue the stock analysis
Jump to another research area for this company.